Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.
Saved in:
| Title: | Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells. |
|---|---|
| Authors: | Hong SW; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Convergence Medicine, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Shin JS; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Convergence Medicine, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Moon JH; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Jung SA; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Koh DI; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Convergence Medicine, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Ryu Y; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Park YS; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Kim DY; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Park SS; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Hong JK; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Kim EH; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Kim MJ; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Jeong HR; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Bae IH; Hanmi Research Center, Hanmi Pharm. Co., Ltd, Gyeonggi-do, Republic of Korea., Ahn YG; Hanmi Research Center, Hanmi Pharm. Co., Ltd, Gyeonggi-do, Republic of Korea., Suh KH; Hanmi Research Center, Hanmi Pharm. Co., Ltd, Gyeonggi-do, Republic of Korea., Cho IJ; Osong Medical Innovation Foundation, Cheongju-si, Republic of Korea., Kang JS; Bioevaluation Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Chungbuk, Republic of Korea., Hong YS; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.; Department of Oncology, Asan Medical Center, Seoul, Republic of Korea., Lee JS; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea.; Department of Oncology, Asan Medical Center, Seoul, Republic of Korea., Jin DH; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea. inno183@amc.seoul.kr.; Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea. inno183@amc.seoul.kr.; Department of Medical Science, Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. inno183@amc.seoul.kr.; Department of Medical Sicence, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. inno183@amc.seoul.kr., Kim TW; Institute for Innovative Cancer Research, Asan Medical Center, Seoul, Republic of Korea. twkimmd@amc.seoul.kr.; Department of Oncology, Asan Medical Center, Seoul, Republic of Korea. twkimmd@amc.seoul.kr. |
| Source: | Investigational new drugs [Invest New Drugs] 2020 Dec; Vol. 38 (6), pp. 1696-1706. Date of Electronic Publication: 2020 May 27. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-0646 |
|---|---|
| DOI: | 10.1007/s10637-020-00956-9 |
